You are here: Industry Insights > Regeneron

News List

Regeneron and Sanofi receive FDA’s breakthrough therapy status for CSCC treatment with cemiplimab pharmaceufical-technology
September 12, 2017
The FDA status will enable the companies to use cemiplimab for the treatment of adults with metastatic CSCC or adults with locally advanced and unresectable CSCC.
Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy desig worldpharmanews
September 11, 2017
Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC)
Regeneron drops RSV therapy on trial failure pharmatimes
August 16, 2017
Regeneron Pharmaceuticals is pulling the plug on an experimental therapy in development for preventing respiratory syncytial virus (RSV) infection in infants, after a disappointing performance in a late-stage trial
Regeneron abandons respiratory syncytial virus therapy after late-stage failure pharmafile
August 16, 2017
Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the company has decided to scrap its further development
Sanofi and Regeneron announce approval of Kevzara to treat rheumatoid arthritis in the European Unio biospectrumasia
June 30, 2017
Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) and blocks pro-inflammatory IL-6 mediated signaling
Sanofi and Regeneron announce EC approval of Kevzara (sarilumab) expressbpd
June 28, 2017
It is used to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union
Regeneron, SillaJen in Clinical and Supply Pact contractpharma
May 09, 2017
To evaluate Regeneron's PD-1 inhibitor in combination with SillaJen's Pexa-Vec in kidney cancer
Financial Report: Regeneron contractpharma
May 05, 2017
Global EYLEA sales were up 12% in the quarter to $1.3 billion. Sales of EYLEA in the U.S. increased 9% to $854 million.
FDA accepts Sanofi and Regeneron’s biologics license resubmission europeanpharmaceuticalreview
May 03, 2017
The US Food and Drug Administration (FDA) has accepted the resubmission of Sanofi and Regeneron Pharmaceuticals’ biologics license application for Kevzara (sarilumab) as a Class I response with a two month review timeline.
Regeneron and Sanofi receive FDA approval of a new once-monthly dosing option for Praluent Injection cphi-online
April 27, 2017
Monthly dosing schedule now approved in both US and EU.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page